2024
A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
Anderson S, Cavaletti G, Hood L, Polydefkis M, Herrmann D, Rance G, King B, McMichael A, Senna M, Kim B, Napatalung L, Wolk R, Zwillich S, Schaefer G, Gong Y, Sisson M, Posner H. A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata. Pharmacology Research & Perspectives 2024, 12: e1204. PMID: 38969959, PMCID: PMC11226387, DOI: 10.1002/prp2.1204.Peer-Reviewed Original ResearchConceptsIntraepidermal nerve fibersWave V amplitudeInterwave latenciesI-V interwave latencyV amplitudeMonth 9Placebo-controlled phasePhase 2a studyAxonal swellingsIENF densityPlacebo groupBAEP changesLoading doseAdverse eventsRitlecitinibAlopecia areataKinase inhibitorsPrimary outcomeHuman doseToxicity findingsBAEPClinical relevanceNerve fibersPhase 2aStimulus intensity
2020
Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata
Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, Dutronc Y, Mesinkovska N, Ko JM, King BA. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata. American Journal Of Clinical Dermatology 2020, 21: 725-732. PMID: 32803546, PMCID: PMC7473969, DOI: 10.1007/s40257-020-00545-9.Peer-Reviewed Original ResearchConceptsSigns/symptomsAlopecia areataPRO measuresNail appearanceEyelash lossOutcome measuresHair lossEye irritationPatient-reported outcome measuresClinician-reported outcomesNorth American patientsDevelopment of cliniciansNail assessmentEyebrow lossNail involvementAmerican patientsClinical trialsPatientsNail damageSymptomsAreataObjectivesOur objectiveOutcomesEyelashesDermatologistsDupilumab as a novel therapy for bullous pemphigoid: A multicenter case series
Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, Gordon S, Ahmed R, Nichols A, Rothe M, Rosmarin D. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. Journal Of The American Academy Of Dermatology 2020, 83: 46-52. PMID: 32179082, DOI: 10.1016/j.jaad.2020.01.089.Peer-Reviewed Original ResearchConceptsBullous pemphigoidDisease clearanceCase seriesSatisfactory responseMulticenter case seriesAutoimmune blistering disorderLesional skin biopsiesSeries of patientsPrevious conventional therapyEnzyme-linked immunosorbentStandardized assessment toolsAdverse eventsDisease improvementConventional therapyClinician documentationTotal clearanceSkin biopsiesNovel therapiesDirect immunofluorescencePatient's desireEosin stainingAdequate treatmentAverage agePatientsAcademic centersTreatment of severe lichen planus with the JAK inhibitor tofacitinib
Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. Journal Of Allergy And Clinical Immunology 2020, 145: 1708-1710.e2. PMID: 32018031, DOI: 10.1016/j.jaci.2020.01.031.Peer-Reviewed Original ResearchJAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea patients
Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. JAK inhibition prevents bleomycin-induced fibrosis in mice and is effective in morphea patients. Journal Of Investigative Dermatology 2020, 140: 1446-1449.e4. PMID: 31954727, DOI: 10.1016/j.jid.2019.12.019.Peer-Reviewed Original Research
2019
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.Peer-Reviewed Original ResearchConceptsGranuloma annulareCutaneous sarcoidosisPathway activationCutaneous granulomatous disordersRecalcitrant cutaneous sarcoidosisSkin biopsy specimensSignal regulatory protein αJAK-STAT pathway activationTranscription (JAK/STAT) pathway activationRegulatory protein αRecalcitrant sarcoidosisSarcoidosis activityDisease remissionConsecutive patientsGranulomatous disorderProspective evaluationBiopsy specimensHistologic resolutionSkin biopsiesMean improvementSarcoidosisImmunohistochemical analysisJAK inhibitorsJAK inhibitionPatients
2017
Lack of efficacy of apremilast in 9 patients with severe alopecia areata
Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. Journal Of The American Academy Of Dermatology 2017, 77: 773-774. PMID: 28917463, DOI: 10.1016/j.jaad.2017.05.034.Peer-Reviewed Original ResearchAdolescentAdultAge FactorsAgedAlopecia AreataAnti-Inflammatory Agents, Non-SteroidalDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansMaleMiddle AgedNeeds AssessmentRetrospective StudiesRisk AssessmentSampling StudiesSeverity of Illness IndexSex FactorsThalidomideTreatment FailureYoung AdultRepigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. Journal Of The American Academy Of Dermatology 2017, 77: 675-682.e1. PMID: 28823882, PMCID: PMC6233876, DOI: 10.1016/j.jaad.2017.05.043.Peer-Reviewed Original ResearchConceptsTreatment of vitiligoJAK inhibitorsConsecutive patientsInhibitor tofacitinibJanus kinase inhibitor tofacitinibJAK inhibitor monotherapyRetrospective case seriesUltraviolet B phototherapyT-cell mediatorsBody surface areaJanus kinase inhibitorSeverity of diseaseB phototherapyInhibitor monotherapyCase seriesAutoimmune responseCell mediatorsAutoimmune diseasesCutaneous depigmentationLight exposureRetrospective natureStudy populationExisting therapiesControl groupTofacitinib
2016
Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib
King B, Lee AI, Choi J. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib. Journal Of Investigative Dermatology 2016, 137: 951-954. PMID: 27887955, PMCID: PMC5387413, DOI: 10.1016/j.jid.2016.10.044.Peer-Reviewed Original ResearchTofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. Journal Of The American Academy Of Dermatology 2016, 76: 22-28. PMID: 27816293, DOI: 10.1016/j.jaad.2016.09.007.Peer-Reviewed Original ResearchConceptsSevere alopecia areataAlopecia areataAlopecia totalisAlopecia universalisPercent changeAlopecia Tool (SALT) scorePatients age 18Primary end pointSerious adverse eventsMonths of treatmentCommon autoimmune disorderSeries of patientsScalp hair lossAdverse eventsClinical responseHigher percent changeAutoimmune disordersRetrospective studyEffective therapyRetrospective natureInclusion criteriaHair lossPotential respondersPatientsTool scoreSafety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge M, Marinkovich MP, Christiano AM, Oro AE, King BA. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 2016, 1: e89776. PMID: 27699252, PMCID: PMC5033755, DOI: 10.1172/jci.insight.89776.Peer-Reviewed Original ResearchConceptsAlopecia areataAlopecia totalisAlopecia universalisHair lossDisease activity index scoreTreatment of AANational Alopecia Areata FoundationActivity index scoreCompletion of therapySevere alopecia areataSingle-arm trialNational Psoriasis FoundationScalp hair lossNational InstituteVeterans Affairs OfficePan-JAK inhibitorAdverse eventsDrug cessationDurable responsesAlopecia ToolDisease relapseTherapeutic optionsAutoimmune diseasesEffective therapyGrade I
2014
When erythema ab igne warrants an evaluation for internal malignancy
Bunick CG, Ibrahim O, King B. When erythema ab igne warrants an evaluation for internal malignancy. International Journal Of Dermatology 2014, 53: e353-e355. PMID: 24601874, DOI: 10.1111/ijd.12329.Peer-Reviewed Original Research